| Date | Title | Description |
| 22.03.2022 | SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson’s Disease | Project to Focus on Creating Dopamine-Producing Neurons Using Direct mRNA-based Reprogramming of Immune Cells
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that it h... |
| 13.09.2021 | SQZ BIOTECHNOLOGIES CO : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | Item 7.01 Regulation FD Disclosure.
On September 13, 2021, SQZ Biotechnologies Company (the "Company") issued a press release titled "SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Ca... |
| 18.05.2020 | SQZ Biotech Closes $65 Million Series D Financing | WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the completion of a $65 million Series D preferred ... |
| 18.05.2020 | SQZ Biotech Closes $65M Series D Round |
WATERTOWN, MA, SQZ Biotechnologies announced the completion of a $65 million Series D preferred stock financing led by Temasek.
>> Click here for more funding data on SQZ Biotech
>> To export SQZ Biotech funding data to PDF ... |
| 18.05.2020 | SQZ Biotech snags $65M to push cancer vaccine, break into infectious disease | SQZ Biotech is looking to propel its lead asset, a cancer vaccine for HPV-positive tumors, through phase 1 and expand its cell-squeezing technology beyond oncology into infectious diseases. And it's reeled in $65 million to do it.
The compa... |
| 18.05.2020 | SQZ Biotech snags $65M to push cancer vaccine, break into infectious disease | SQZ Biotech is looking to propel its lead asset, a cancer vaccine for HPV-positive tumors, through phase 1 and expand its cell-squeezing technology beyond oncology into infectious diseases. And it's reeled in $65 million to do it.
Sponsored... |
| 19.11.2019 | “Squeezing” Cells Could Transform Cell Therapy Manufacturing | Manufacturing today’s cell therapies remains expensive and complex due to the need for viruses or electric shocks to engineer patient cells. Yescarta®, for example, one of the first CAR-T therapies approved for sale, takes 3-4 weeks to reac... |
| 15.10.2018 | SQZ, Roche beef up cell therapy partnership | The original partnership announcement included a deal for more than $500 million in upfront and clinical, regulatory and sales milestones. The latest news follows the company’s August announcement that it had closed an oversubscribed Series... |
| 15.10.2018 | SQZ Biotech Expands Cell Therapy Partnership with Roche to Develop Antigen Presenting Cells for Immune-Oncology | October 15, 2018 – Watertown, MA – SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the expansion of its collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) in c... |
| 10.08.2018 | Term Sheet — Friday, August 10 | MORE DEBT
Happy Friday, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
According to the WSJ, the note, which accrues interest of 2.8% a year starting next September, gives WeWork the ability to foc... |
| 08.08.2018 | SQZ Biotech raises $72M in Series C funding round | The company will initially apply its lead program, in antigen-presenting cells, in a number of human papillomavirus-related tumor indications, while future applications will address solid tumors across cancer types. That program is in precl... |
| 08.08.2018 | Cell Therapy Company SQZ Biotechnologies Completes $72M Series C Financing | SQZ Biotechnologies, a Watertown, Mass.-based cell therapy company developing novel treatments for multiple therapeutic areas, completed a $72m Series C financing.
New investors included Everblue, Illumina Ventures, Invus, Orient Life, and ... |
| 08.08.2018 | SQZ Biotech Completes Oversubscribed $72 Million Series C Financing | SQZ advancing cell therapy pipeline toward clinical trials in multiple indications, Company Board of Directors expands with addition of Marc Elia and Zafi Avnur, PhD. |
| 08.08.2018 | SQZ Biotech Completes $72 Million Series C Financing | SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced the completion of an oversubscribed $72 million Series C financing. New investors include Everblue, Illumina Ventures, I... |
| 08.08.2018 | SQZ raises $72M as cell therapies close in on clinical trials
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | SQZ Biotechnologies has raised $72 million. The series C round sets the Roche-partnered MIT spinout to advance cell therapy treatments of solid tumors and autoimmune diseases toward the clinic.
Massachusetts-based SQZ made waves a few years... |
| 08.08.2018 | SQZ Biotech Completes $72M Series C Round |
WATERTOWN, MA, Cell therapy company developing novel treatments for multiple therapeutic areas, has completed an oversubscribed $72M Series C financing.
>> Click here for more funding data on SQZ Biotech
>> To export SQZ Bio... |
| 08.08.2018 | SQZ raises $72M as cell therapies close in on clinical trials | SQZ Biotechnologies has raised $72 million. The series C round sets the Roche-partnered MIT spinout to advance cell therapy treatments of solid tumors and autoimmune diseases toward the clinic.
Massachusetts-based SQZ made waves a few years... |
| 06.12.2017 | Term Sheet — Wednesday December 6 | UNCENSORED
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
Today, we had Alibaba’s Jack Ma, Apple’s Tim Cook, Tencent’s Pony Ma, and Ford’s Bill Ford. You can find the full cover... |
| 05.12.2017 | SQZ Biotech Receives Investment from JDRF T1D Fund | SQZ Biotech, a Watertown, Massachusetts-based preclinical stage biotechnology company, received an investment of undisclosed amount from the JDRF T1D Fund.
With the investment, the T1D Fund also provides the expertise of JDRF, the global or... |
| 05.12.2017 | SQZ Biotech Receives Investment from JDRF T1D Fund | SQZ Biotech (SQZ), a preclinical stage biotechnology company, announced today that it has received an investment from the JDRF T1D Fund to provide support for development of the Company's novel therapy for type 1 diabetes (T1D) aimed at ret... |
| 02.12.2016 | SQZ Biotech Adds $4M to Series B |
BOSTON, MA, Quark Venture, a Vancouver-based venture capital company, announced a $4 million investment in SQZ Biotech.
>> Click here for more funding data on SQZ Biotech
>> To export SQZ Biotech funding data to PDF and Exce... |
| 02.12.2016 | Term Sheet — Friday, December 2 | ET CETERA
• This week Twitter (or at least my corner of it) has been buzzing over an essay penned by Om Malik about the tech industry’s lack of empathy for the people its products hurt. For example, Otto, the self-driving truck startup, wil... |
| 01.12.2016 | SQZ Biotech Raises Further $4M in Series B Funding | SQZ Biotech, a Boston, MA-based developer of cell engineering technology that harnesses the body’s natural immune system to combat disease, raised $4m in Series B funding.
Quark Venture made the investment joining GV, NanoDimension, Polaris... |
| 02.10.2016 | SQZ Biotech Raises $16 Million Series B | BOSTON--(BUSINESS WIRE)--SQZ Biotech announced today the closing of a $16 million Series B financing round led by NanoDimension and Polaris Partners, with participation from other existing and new investors. Using its breakthrough cell engi... |
| 30.09.2016 | SQZ Biotech Announces $16M Series B Funding |
BOSTON, MA, SQZ Biotech announced today the closing of a $16 million Series B financing round led by NanoDimension and Polaris Partners.
>> Click here for more funding data on SQZ Biotech
>> To export SQZ Biotech funding dat... |
| 30.09.2016 | SQZ Biotech Closes $16M Series B Financing | SQZ Biotech, a Boston, MA-based developer of a new generation of cell therapies that harness the body’s natural immune system to combat disease, closed a $16m Series B financing.
The round was led by NanoDimension and Polaris Partners, with... |
| 24.06.2015 | SQZ Biotech Raises $5M Series A |
BOSTON, MA, Pioneering company whose CellSqueeze platform enables a variety of materials to enter a cell with unprecedented efficacy, announced today $5 million in Series A funding.
>> Click here for more funding data on SQZ Biotec... |
| 24.06.2015 | SQZ Biotech Raises $5M in Series A Funding | SQZ Biotech (SQZ), a Boston, MA-based developer of a platform that enables a variety of materials to enter a cell, raised $5m in Series A funding.
The round was led by Polaris Partners with participation from 20/20 Healthcare Partners and o... |
| 23.12.2014 | Sick of immunotherapy? These biotech/medtech startups are doing something different. | ZipLine Medical
Stapling up skin post-surgery is pretty much the norm to quickly seal up wounds, but it runs a risk of infection and injury from the extra damage to already sensitive skin. This Bay Area startup has a non-invasive, non-sutur... |
| 06.11.2014 | SQZBiotech’s “cell-squeezing” wins top accolades at MassChallenge, headed to outer space | SQZBiotech, founded in 2013, was one of four startups to win $100K in MassChallenge’s prestigious 2014 competition – and nabbed another $200K from Boeing and the Center for Advancement of Science in Space. The reason this cell-squeezing cou... |
| 29.10.2014 | MassChallenge Celebrates Highest-Impact Startups from 2014 | MassChallenge and ~1,700 members of the Boston startup community gathered to celebrate entrepreneurship at the fifth-annual MassChallenge Awards Ceremony. The event featured pitches from the Top 26 startups, and speeches from Governor Deval... |
| 14.10.2014 | MassChallenge Announces Top 26 Finalists from Most Competitive Class Ever | Our entrepreneurs had a rigorous summer and Im very proud of all startups from the 2014 class, said MassChallenge Founder and President Akhil Nigam. These top 26 startups are poised to make a tremendous impact across a variety of industries... |
| - | SQZ, Roche beef up cell therapy partnership | Just two months after closing a Series C financing round, a small US-based biotech firm is expanding a partnership with one of the world’s largest drugmakers.
Watertown, Massachusetts-based SQZ Biotechnologies said Monday it will expand its... |
| - | SQZ Biotechnologies Reports 2020 Financial Results and Recent Advancements | WATERTOWN, Mass.--(BUSINESS WIRE)--Mar 18, 2021--
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and recent business highli... |
| - | SQZBiotech’s “cell-squeezing” wins top accolades at MassChallenge, headed to outer space | Fresh off its MassChallenge win, MIT spinoff SQZBiotech is taking its tech to new heights. Namely, it’s partnered with NASA and will be studying its “cell-squeezing” process at the International Space Station, learning how to better insert ... |
| - | Sick of immunotherapy? These biotech/medtech startups are doing something different. | We’re in the era of immunotherapy, of monoclonal antibodies and anti-inflammation drugs and personalized medicine. Insert buzzword. Startups in these spaces tend to attract a sizable swath of cash, particularly if they’re in the lucrative c... |
| - | SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs at the American Association for Cancer Research (AACR) 2021 Annual Meeting | WATERTOWN, Mass.--(BUSINESS WIRE)--Mar 10, 2021--
SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present data on the next genera... |
| - | SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference | WATERTOWN, Mass.--(BUSINESS WIRE)--Mar 3, 2021--
SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ™, wil... |
| - | SQZ Biotech raises $72M in Series C funding round | A company developing cell therapies for cancers and autoimmune diseases has closed a financing round three times the size of the last one.
Watertown, Massachusetts-based SQZ Biotechnologies said Wednesday that it had raised $72 million in a... |
